MEDADVISOR LIMITED (MDR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MDR

MDR - MEDADVISOR LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.83
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.10

24 Mar
2025

0.000

OPEN

$0.11

0.000

HIGH

$0.11

541,538

LOW

$0.10

TARGET
$0.21 110.0% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
MDR: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 0.1 - 1.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx122.1 M
Book Value Per Share xxxxxxxxxxxxxxx9.4
Net Operating Cash Flow xxxxxxxxxxxxxxx5.2 M
Net Profit Margin xxxxxxxxxxxxxxx0.65 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx1.58 %
Return on Invested Capital xxxxxxxxxxxxxxx1.41 %
Return on Assets xxxxxxxxxxxxxxx0.81 %
Return on Equity xxxxxxxxxxxxxxx1.58 %
Return on Total Capital xxxxxxxxxxxxxxx4.29 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx5.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx13 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx13 M
Goodwill - Gross xxxxxxxxxxxxxxx46 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx16 M
Price To Book Value xxxxxxxxxxxxxxx5.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1.8 M
Capex % of Sales xxxxxxxxxxxxxxx1.50 %
Cost of Goods Sold xxxxxxxxxxxxxxx98 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx21 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

31/01/2025

3

Downgrade to Hold from Buy

$0.21

110.00%

Bell Potter cuts its target price for MedAdvisor to 21c from 40c and downgrades to Hold from Buy, due to reduced earnings forecasts and a lower assumed valuation multiple.

Second quarter revenue fell short of the growth expectations set by management at the start of FY25, with US revenue declining by -29% in the first half due to lower vaccine contract revenue, which the broker sees as the most significant factor.

Non-vaccine revenue for H1 also dropped by -24% year-on-year, while Australian revenue rose by just 2%. Management did not reiterate its FY25 positive earnings (EBITDA) guidance from the December trading update.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.00 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Moelis

05/03/2025

3

Hold

$0.19

90.00%

Moelis notes MedAdvisor’s 1H25 EBITDA came in at $4.8m but the company didn't reaffirm prior guidance for positive EBITDA in 2H or FY25, and also didn't reiterate its outlook for y/y uplift in US revenue in 2H.

management pointed to the US pipeline which represents 160% of the revenue required to achieve the 2H forecast, but the broker is cautious, given previous conversions have been slower than expected.

The broker believes the company will need to grow its program and expand into new areas to maintain US profits. 

Moelis lowered 2H revenue and also cut opex costs as a result of the January restructure. Target price drops to 19c from 21c, and Hold rating stays.

FORECAST
Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.80 cents.
Access Extra Coverage Research History >

MDR STOCK CHART

FNArena News on MDR

1
In Case You Missed It – BC Extra Upgrades & Downgrades – 14-03-25

Mar 14 2025 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Mar 10, 2025

Mar 10 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Mar 05, 2025

Mar 05 2025 - Daily Market Reports
4
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-02-25

Feb 07 2025 - Weekly Reports
5
Rudi’s View: Earnings Optimism On The Rise

Feb 05 2025 - Rudi's View

Latest Healthcare services News

1
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
2
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
3
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
4
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
5
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
6
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
7
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
8
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
9
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
10
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps